Advancing therapeutic insights: The impact of understanding cellular target engagement with NanoBRET® technology

FHS
May 30, 2024
9:17 am

In this Interview, NewsMedical speaks with Amy Landreman about NanoBRET® Technology and its role in cellular target engagement.

Medicare to Cover Weight-Loss Drug Wegovy for Certain Patients

Medicare will cover the weight-loss drug semaglutide (Wegovy) under its Part D drug program for patients with overweight or obesity who have preexisting heart disease

March 22, 2024

New Biden initiative targets controversial hospital ‘facility fees’ that often surprise patients

As part of the Biden administration’s broader efforts to lower health care costs, the White House announced new guidelines on Friday targeting a few of

July 7, 2023

RPA-601 by Rocket Pharmaceuticals for Cardiomyopathy: Likelihood of Approval

RPA-601 is under clinical development by Rocket Pharmaceuticals and currently in Phase I for Cardiomyopathy.

November 5, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.